SCHEMBL3111168

SCHEMBL3111168

[O-][n+]1c(-c2ccccc2O)ncc2ccccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
IDO1 P14902 4/20 0.35
RIPK1 Q13546 1/20 0.35
QPCT Q16769 1/20 0.35
QPCTL Q9NXS2 1/20 0.35
F7 P08709 1/20 0.34
ALDH1A1 P00352 2/20 0.33
HPGD P15428 2/20 0.33
HSD17B10 Q99714 2/20 0.33
BCL2L1 Q07817 1/20 0.33
CASP3 P42574 1/20 0.33
SENP8 Q96LD8 1/20 0.33
SENP7 Q9BQF6 1/20 0.33
SENP6 Q9GZR1 1/20 0.33
ILK Q13418 1/20 0.33
MAPK1 P28482 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5250885 0.76 ATM (0.45) ATMSMN1; SMN2ALDH1A1KDM4ELMNA
SCHEMBL4559941 0.75 ATM (0.48) ATMMEN1KMT2AKDM4ETSHR
SCHEMBL15066601 0.71 ATM (0.44) ATML3MBTL1SMN1; SMN2RIPK1QPCT
SCHEMBL6557052 0.70 ATM (0.36) ATMKDM4E
SCHEMBL5259264 0.68 ATM (0.48) ATMMEN1KMT2AKDM4EPOLB
SCHEMBL4620642 0.68 ATM (0.48) ATMMEN1KMT2AKDM4EPOLB
SCHEMBL8424490 0.68 ATM (0.48) ATMMEN1KMT2AKDM4EPOLB
SCHEMBL3535166 0.68 ATM (0.48) ATMMEN1KMT2AKDM4EMAPT
SCHEMBL9769252 0.66 ATM (0.45) ATMKDM4E
SCHEMBL2360187 0.66 CYP1A2 (0.56) L3MBTL1SMN1; SMN2ALDH1A1HPGDCASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100249161-A1 2- ( 2 -HYDROXYPHENYL) -QUINAZOLIN-4-ONES USEFUL FOR TREATING OBESITY AND DIABETES HIGH POINT PHARMACEUTICALS, LLC 2010-09-30 US disclosed
EP-2097391-A1 2- ( 2 -HYDROXYPHENYL) -QUINAZOLIN-4-ONES USEFUL FOR TREATING OBESITY AND DIABETES High Point Pharmaceuticals, LLC (US) 2009-09-09 EP disclosed
WO-2008059024-A1 2- ( 2 -HYDROXYPHENYL) -QUINAZOLIN-4-ONES USEFUL FOR TREATING OBESITY AND DIABETES HIGH POINT PHARMACEUTICALS, LLC (US) 2008-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249161-A1 2- ( 2 -HYDROXYPHENYL) -QUINAZOLIN-4-ONES USEFUL FOR TREATING OBESITY AND DIABETES GPR119, PGC, FABP4 ATM 4559/4885L3MBTL1 2032/4885SMN1; SMN2 4537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.